Page last updated: 2024-08-25

2-aminopyrazine and Leukemia, Myelomonocytic, Acute

2-aminopyrazine has been researched along with Leukemia, Myelomonocytic, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aleskog, A; Ekholm, C; Eriksson, A; Fhölenhag, K; Hassan, SB; Höglund, M; Jensen, AJ; Larsson, R; Lindhagen, E; Löthgren, A; Parrow, V; Scobie, M	1

Other Studies

1 other study(ies) available for 2-aminopyrazine and Leukemia, Myelomonocytic, Acute

Article	Year
Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia. Biochemical pharmacology, 2010, Nov-15, Volume: 80, Issue:10 Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Epithelial Cells; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Acute; Male; Mice; Middle Aged; Molecular Structure; Pyrazines; Xenograft Model Antitumor Assays; Young Adult	2010

Article

Year

Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.

Biochemical pharmacology, 2010, Nov-15, Volume: 80, Issue:10

Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Epithelial Cells; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Acute; Male; Mice; Middle Aged; Molecular Structure; Pyrazines; Xenograft Model Antitumor Assays; Young Adult

2010